Evidence map›Paper›PMID 32769922›Full record

SynthesisMedicine2020

A systematic review and meta-analysis of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine in the treatment of COVID-19.

Xuemei Wang, Ping Xie, Guojuan Sun, Zhumei Deng, Min Zhao, Shuting Bao, Yunxia Zhou

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 4 countries.

Xuemei WangDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.ORCID 0000-0003-2108-1789
Ping XieDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P. R. China.
Guojuan SunDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Zhumei DengDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Min ZhaoDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Shuting BaoDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Yunxia ZhouDepartment of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Weatherford College · USChengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 is a global public health emergency. At present, there is no highly effective medicine for the prevention and treatment of 2019-nCoV. Western medicine for COVID-19 is mainly based on symptomatic support therapy. Chinese herbal medicine has been used to prevent infectious diseases for thousands of years in China. Western medicine routine treatment combined with Chinese herbal medicine is an alternative clinical option but lacks evidence-based medical evidence. The systematic review protocol aims to formulate a research plan that can evaluate the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine for COVID-19.

methodsWe will search the following eight databases: Cochrane Library, PubMed, Embase, Medline, CNKI, Wanfang, VIP, and CBM. The search time is up to the end of July 2020. Two authors will independently complete literature screening, data extraction, and risk of bias assessment. In case of disagreement, the third author will assist in the judgment. The primary outcome will be the clinical cure rate. The secondary outcome will be accounting symptoms, fever time, time of virus nucleic acid turning negative, check the condition by drawing blood, pneumonia absorption rate, patient hospitalization time, severe conversion rate and case fatality rate, adverse reactions, and adverse events. Revman 5.3 will be used for systematic reviews and meta-analysis. The report of the protocol will follow the PRISMA-P statement, and the report of the systematic review and meta-analysis will follow the PRISMA statement.

resultsWe will provide evidence-based medical evidence of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine for COVID-19. The findings will be published in peer-reviewed journals. REGISTRATION DETAILS: CRD42020190106.

Indexed as

Treatment OutcomeAnti-Infective AgentsAntiviral AgentsChinaCombined Modality TherapyCoronavirus InfectionsCOVID-19Drugs, Chinese HerbalFemaleHumansMaleMedicine, Chinese TraditionalPandemicsPatient SafetyPneumonia, ViralSevere Acute Respiratory SyndromeAnti-Infective AgentsAntiviral AgentsDrugs, Chinese Herbal

Identifiers

PMID32769922
PMCPMC7593006
OpenAlexW3047124452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.